Eli Lilly (LLY) gets FTC clearance for the acquisition of Innovent Biologics (1801 HK)

Newsquawk StaffPublished
Newsquawk headlinesUTC

Every headline is on the live feed 20 minutes before this site.

US EQUITY OPEN: Stocks hit on geopolitics and private credit woes

The US is to release 2026-27 biofuel blending quotes this week, according to sources; mandate has not materially changed despite energy supply concerns

Eli Lilly (LLY) gets FTC clearance for the acquisition of Innovent Biologics (1801 HK)

US S&P Global Manufacturing PMI Flash (Mar) 52.4 vs. Exp. 51 (Prev. 51.6, Low. 50.5, High. 52.2)

US S&P Global Services PMI Flash (Mar) 51.1 vs. Exp. 51.7 (Prev. 51.7, Low. 50.5, High. 52.5)

On the Newsquawk feed at , 20 minutes before this page.

Use the PlatformFree. No signup, no card.

Context

Eli Lilly's clearance from the FTC for its acquisition of Innovent Biologics is a significant step forward, indicating that regulatory hurdles are being cleared for this strategic move. This deal could enhance Eli Lilly's portfolio in the biotechnology space, potentially leading to increased market competitiveness and future revenue streams. Keep an eye on how this development influences Eli Lilly's stock price and overall sector dynamics.

Related headlines

The feed had this first.

Use the Platform